Promyelocytic leukemia nuclear body disruption as a treatment for EBV-associated nasopharyngeal carcinoma?

ISSN： 1746-0794

Source： Future Virology, Vol.7, Iss.1, 2012-01, pp. : 1-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Promyelocytic leukemia-nuclear body proteins: herpesvirus enemies, accomplices, or both?

By Saffert Ryan T Kalejta Robert F

Future Virology, Vol. 3, Iss. 3, 2008-05 ,pp. : 265-277

Future Medicine

Access to resources Recommend Favorite

Strategies for the Treatment of Acute Promyelocytic Leukemia

By Frankfurt Olga Tallman Martin S.

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 4, Iss. 1, 2006-01 ,pp. : 37-50

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Azathioprine: EBV-associated lymphoproliferative disorder: case report

Reactions Weekly, Vol. 1, Iss. 1318, 2010-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Azathioprine: EBV-associated Hodgkin's lymphoma: case report

Reactions Weekly, Vol. 1, Iss. 1208, 2008-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Azathioprine: EBV-associated Hodgkin's lymphoma: case report

Reactions Weekly, Vol. 1, Iss. 1197, 2008-01 ,pp. : 9-10

Adis International

Access to resources Recommend Favorite